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Abstract
Autophagy is a lysosomal degradation pathway that eliminates aggregated proteins and damaged 
organelles to maintain cellular homeostasis. A major route for activating autophagy involves 
inhibition of the mTORC1 kinase, but current mTORC1-targeting compounds do not allow 
complete and selective mTORC1 blockade. Here, we have coupled screening of a covalent ligand 
library with activity-based protein profiling to discover EN6, a small-molecule in vivo activator of 
autophagy that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal v-
ATPase, which activates mTORC1 via the Rag guanosine triphosphatases. EN6-mediated 
ATP6V1A modification decouples the v-ATPase from the Rags, leading to inhibition of mTORC1 
signaling, increased lysosomal acidification, and activation of autophagy. Consistently, EN6 clears 
TDP-43 aggregates, a causative agent in frontotemporal dementia, in a lysosome-dependent 
manner. Our results provide insight into how the v-ATPase regulates mTORC1, and reveal a 
unique approach for enhancing cellular clearance based on covalent inhibition of lysosomal 
mTORC1 signaling.
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We report here a covalent ligand that targets C277 of ATP6V1A leading to enhanced v-ATPase 
activity, inhibition of mTORC1 signaling, increasesd lysosomal acidification, activation of 
autophagy, and clearance of toxic protein aggregates.
Keywords
autophagy; chemoproteomics; activity-based protein profiling; cysteine; covalent ligand; 
mTORC1; v-ATPase; lysosome; ATP6V1A
Introduction
Autophagy is central to the maintenance of organismal homeostasis in both physiological 
and pathological situations. It is an essential, conserved lysosomal degradation pathway that 
controls the quality of the cytoplasm by eliminating aggregated proteins and damaged 
organelles. Accordingly, alterations in autophagy have been linked to a wide range of 
diseases and conditions, including aging, cancer, metabolic disorders, and neurodegenerative 
diseases 1,2. Throughout the past decade, autophagy has attracted considerable attention as a 
target for the development of novel therapeutics 3,4.
The activity of the autophagic machinery is tightly linked to upstream signals from nutrients, 
energy and stressors through the mechanistic target of rapamycin complex 1 (mTORC1) 
protein kinase. mTORC1 phosphorylates and inhibits a master switch for autophagosome 
formation, the ULK1 kinase along with its accessory factor Atg13 5,6. Moreover, mTORC1 
blocks the nuclear translocation and activation of the MiT/TFE family transcription factor 
TFEB which, along with closely related TFE3, functions as a ‘master regulator’ of 
catabolism by coordinately promoting the expression of genes required for autophagosome 
formation and lysosomal function 5–7. Inhibition of mTORC1 resulting from starvation or 
chemical inhibitors triggers autophagy by simultaneously unleashing the activity of ULK1 
and TFEB. Thus, chemical inhibition of mTORC1 is viewed as a prime strategy for 
activating autophagy in physiological settings.
Most protein misfolding diseases are associated with intracytoplasmic deposition of 
aggregate-prone proteins in neurons and non-neuronal cells, which impair essential cellular 
pathways for transport, energy production and quality control 8. Over recent years, evidence 
has accumulated to demonstrate that upregulation of autophagy is protective against 
neurodegeneration. In particular, aggregate-prone proteins that drive the toxicity of 
Huntington’s disease (HD), Amyotrophic Lateral Sclerosis (ALS) and Fronto-Temporal 
Dementia (FTD) among others are autophagic substrates, and pharmacological activators of 
autophagy can be beneficial in both cell and animal models of these diseases, by both 
degrading intracytoplasmic aggregates and by preventing associated cell death 9–11.
While several autophagy-modulating agents have been discovered, many of these 
compounds do not possess the required specificity to activate autophagy in a safe manner, 
either due to off-target effects or due to multiple functions of their target protein. The 
allosteric mTORC1 inhibitor, rapamycin, results in the relatively specific inhibition of 
mTORC1 by causing its binding to FK506-binding protein 1A (FKBP1A) . However, 
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rapamycin is an incomplete mTORC1 inhibitor; most notably it largely fails at blocking 
mTORC1-dependent inhibitory phosphorylation of ULK1 and TFEB and at triggering their 
pro-catabolic programs. Thus, despite some early success in vitro, rapamycin-based drugs 
(Rapalogues) have proven ineffective in reducing neurotoxic protein aggregates 12,13. The 
recently developed ‘ATP-competitive’ compounds block the kinase activity of mTOR toward 
virtually all substrates. The higher potency and broader range of ATP-competitive mTOR 
inhibitors has led to promising results in cancer clinical trials; however, these compounds 
have shown considerable side-effects and the ability to cause substantial toxicity to 
pancreatic β-cell islets leading to β-cell death. Most relevant in the context of 
neurodegenerative disease, ATP competitive mTOR inhibitors strongly suppress Akt 
signaling, which is an essential survival signal for neuronal cells 14–16. The limitations of 
current mTOR inhibitors thus create an urgent need to identify new targets that could lead to 
activation of autophagy while avoiding unacceptable toxicities.
To be activated, mTORC1 needs to translocate to the lysosome membrane 5,6. Nutrients, 
including amino acids, glucose and cholesterol, regulate the lysosomal recruitment of 
mTORC1 by modulating the nucleotide state of the Rag GTPases 17–19. The Rags assemble 
as obligate heterodimers composed of RagA or RagB (which are highly similar to each 
other) associated with RagC or RagD, and are tethered to the lysosomal membrane by the 
pentameric Ragulator complex, composed of the LAMTOR1–5 proteins 17,20,21. Under 
amino acid sufficiency, the Rag GTPases become active by adopting a nucleotide state in 
which Rag-A/B is GTP-loaded and Rag-C/D is GDP-loaded, and mediate the lysosomal 
attachment of mTORC1 by directly interacting with the mTORC1 subunit Raptor 17,20,21.
A key but poorly understood player in Rag-mTORC1 activation is the vacuolar H+ ATPase 
(v-ATPase), an evolutionarily conserved ATP-driven rotary proton pump that couples ATP 
hydrolysis by its peripheral V1 domain to proton translocation through membrane integral 
V0 domain to acidify the lysosome and enable its degradative functions 22,23. The v-ATPase 
forms a physical supercomplex with Ragulator and the Rag GTPases, and its integrity and 
activity are essential for lysosomal mTORC1 recruitment in response to amino acids 
18,24–26
. Although its precise role in Rag-mTORC1 activation is not completely understood, 
the v-ATPase represents a prime target for discovery of small molecules that may 
simultaneously block mTORC1 activation and enhance autophagic function. In this study, 
through the coupling of chemoproteomics and covalent ligand screening, we have 
discovered a small-molecule activator of autophagy that acts through covalent targeting of a 
unique regulatory cysteine on ATP6V1A, resulting in the complete inactivation of mTORC1 
without affecting off-target Akt signaling pathways, and enhanced cellular clearance of toxic 
protein aggregates.
Results
Covalent Screen Reveals EN6 as an Autophagy Activator
To simultaneously discover new targets, druggable hotspots and small-molecule modulators 
for activating autophagy, we screened a library of 217 cysteine- and lysine-reactive ligands 
based on acrylamide, chloroacetamide, and dichlorotriazine scaffolds in a cell-based 
autophagic flux assay that utilizes a dual-color, cleavable LC3B reporter 27–30. By running 
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this screen in mouse embryonic fibroblast (MEF) cells, we identified several covalent 
ligands that increased LC3B processing and thus potentially increased autophagy activation 
(Supplementary Fig. 1a, Supplementary Tables 1–4, Supplementary Dataset 1). mTORC1 
inhibitors rapamycin and Torin1 also demonstrated expected efficacy in this assay. Upon 
replication in human HEK293A cells, the screen yielded the cysteine-reactive acrylamide 
EN6 (1) as an inducer of LC3B degradation to a comparable degree to direct mTORC1 
inhibitors, rapamycin and Torin1 (Fig. 1a–1c). We validated these findings by showing that, 
in HEK293A cells, EN6 treatment increased the levels of processed LC3BII (Fig. 1d), and 
triggered formation of LC3 puncta to a similar degree to Torin1 treatment in a time- and 
dose-dependent manner (Fig. 1e; Supplementary Fig. 1b–S1d). EN6 treatment in HEK293A 
cells also led to significant increases in the number autophagosomes and autolysosomes 
(Supplementary Fig. 1e–1f).
Chemoproteomics Identifies v-ATPase as an EN6 Target
To discover the mechanism of action of EN6, we next mapped its proteome-wide cysteine-
reactivity in MEF cells using competitive isotopic tandem orthogonal proteolysis-enabled 
activity-based protein profiling (isoTOP-ABPP) (Supplementary Fig. 2a, Fig. 2a, 
Supplementary Dataset 2). Upon in situ treatment of cells with vehicle or EN6, we labeled 
the resulting cell lysates with the cysteine-reactive alkyne-functionalized iodoacetamide 
probe (IA-alkyne) followed by the isoTOP-ABPP chemoproteomics pipeline 31–33. The 
primary labeling site of EN6 was identified as cysteine 277 (C277) of ATP6V1A, the 
catalytic subunit of the lysosomal v-ATPase (Fig. 2a). This site showed an isotopic light-to-
heavy (control-to-EN6-treated) ratio of 6.3, indicating target engagement of this site 
compared to other sites. We confirmed this interaction by demonstrating that EN6 displaced 
tetramethylrhodamine-5-iodoacetamide dihydroiodide (IA-rhodamine) labeling from 
recombinant human ATP6V1A protein with an IC50 of 1.7 μM (Fig. 2b). The incomplete 
inhibition of IA-rhodamine labeling by EN6 likely indicates reactivity of the IA-rhodamine 
probe with other ligandable sites within ATP6V1A that are not engaged by EN6 34.
EN6 Blocks mTORC1 Lysosomal Localization and Activation
Previous studies have shown that the lysosomal v-ATPase physically interacts with the 
Ragulator-Rag complex and enables it to recruit mTORC1, leading to activation of 
mTORC1-dependent anabolic programs and inhibition of autophagy initiation 18,26. We thus 
asked whether, by binding to the ATP6V1A subunit of the v-ATPase, EN6 may disrupt 
mTORC1 recruitment to the lysosome, thus leading to its observed autophagy-activating 
effects. Consistent with this premise, we found that EN6 treatment in cells led to complete 
inactivation of mTORC1 signaling, as shown by reduced levels of phosphorylated canonical 
substrates, S6 kinase 1 (S6K1), 4EBP1, and ULK1, in a dose-responsive and time-dependent 
manner (Fig. 2c, Supplementary Fig. 2b–2c). Notably, consistent with specific involvement 
of the v-ATPase in mTORC1 but not mTORC2 regulation, treatment with EN6 had no effect 
on mTORC2-dependent AKT phosphorylation, whereas the ATP-competitive mTOR 
inhibitor, Torin1, blocked AKT phosphorylation completely (Fig. 2c, Supplementary Fig. 
2d).
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Confirming that mTORC1 inhibition by EN6 involves modification of C277 of ATP6V1A, 
phosphorylation of S6K and ULK1 were completely resistant to EN6-mediated inhibition in 
cells in which endogenous ATP6V1A was knocked down and replaced with the non-
modifiable C277A or C277S mutants (Fig. 2d, Supplementary Fig. 2e, 2f and 2g). Mutation 
of C277 to an alanine or serine did not affect v-ATPase activity or its sensitivity to the v-
ATPase inhibitor bafilomycin A1 (BafA1), as shown in a lysosomal re-acidification assay in 
vitro that monitors v-ATPase-dependent quenching of pH-sensitive FITC-conjugated dextran 
18,35
 (Supplementary Fig. 2g). In these cells, EN6-induced LC3BII accumulation and p62/
SQSTM1 degradation were also prevented by the C277A and C277S substitutions, 
indicating that autophagy activation by EN6 is also strictly dependent on C277 modification 
(Fig. 2d, Supplementary Fig. 2h). To further demonstrate that the activity of EN6 is driven 
by covalent modification by the acrylamide cysteine-reactive warhead, we showed that 
treatment of HEK293A cells with a cysteine non-reactive analog of EN6, CC2–49 (2), did 
not inhibit mTORC1 signaling or elevate LC3BII levels (Supplementary Fig. 2i–2j).
The v-ATPase interacts with Ragulator-Rags to enable GTP loading of RagA/B, leading to 
recruitment of mTORC1 to the lysosome 18,26. Consistent with an inhibitory mechanism 
towards this pathway, EN6 was completely ineffective at blocking mTORC1 signaling in 
cells either expressing a constitutively active, GTP-locked RagBQ99L mutant protein, or in 
cells with knockout of the GATOR1 complex protein NPRL3, which promotes GTP 
hydrolysis of RagA/B to inactivate them (Fig. 3a–3b) 36. Further supporting an inhibitory 
action via the Rag GTPases, EN6 treatment completely abrogated amino acid-induced 
mTORC1 recruitment to LAMP2-positive lysosomes, and this effect was prevented by 
exogenously expressing the GTP-locked RagBQ99L mutant protein (Fig. 3c–3d; 
Supplementary Fig. 3).
Although how the v-ATPase promotes GTP loading of RagA/B is not understood, its action 
involves physical interaction with the Ragulator-Rags complex that is modulated by amino 
acids 18,26. Consistently, FLAG-tagged Ragulator subunit p14 immunoprecipitated multiple 
v-ATPase subunits in an amino acid-regulated manner (Fig. 3e). Notably, EN6 decreased the 
overall binding between the v-ATPase and Ragulator and rendered this interaction 
insensitive to amino acids (Fig. 3e). The most parsimonious explanation for this result is that 
covalent modification of C277 of ATP6V1A by EN6 causes a conformational change in the 
v-ATPase that partially decouples it from Ragulator-Rag and prevents activation of the latter 
complex by amino acids. Collectively, these data reveal that, by targeting C277 of 
ATP6V1A, EN6 impairs Rag GTPase-mediated recruitment of mTORC1 to the lysosome, 
leading to starvation-independent induction of autophagy.
EN6 Activates the v-ATPase and Lysosome Acidification
mTORC1 inhibition leads to upregulation of the catabolic functions of the lysosome through 
dephosphorylation and nuclear translocation of TFEB 5,7,37,38. Consistently, upon EN6 
treatment we observed greatly enhanced TFEB nuclear translocation (Fig. 4a, 
Supplementary Fig. 4a) and significantly increased levels of several lysosomal gene 
transcripts that are direct TFEB transcriptional targets, including v-ATPase components (Fig. 
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4b, Supplementary Fig. 4b). In contrast, the expression levels of several genes that are not 
TFEB targets were unchanged (Supplementary Fig. 4c).
Consistent with transcriptional upregulation of the v-ATPase and other lysosomal 
components, EN6 treatment led to significantly increased acidification of the lysosome in 
HEK293A cells, as shown by ratiometric LysoSensor DND-160 staining, and this 
heightened acidification was blocked by BafA1 (Fig. 4c, 4d; Supplementary Fig. 4d). 
Intriguingly, while BafA1 expectedly inhibited in vitro v-ATPase activity, EN6 treatment 
increased the catalytic activity of the v-ATPase, as shown by accelerated acidification of 
FITC-dextran-loaded lysosomes in vitro (Fig. 4e). Thus, the increased lysosomal 
acidification observed with EN6 is likely due to a combination of increased expression of v-
ATPase catalytic subunits and direct stimulation of v-ATPase catalytic activity.
EN6 Promotes Autophagic Clearance of Protein Aggregates
To determine whether EN6-mediated inhibition of mTORC1 and activation of autophagy 
could aid in boosting cellular clearance, we tested the effect of EN6 in clearing toxic Tar-
binding protein 43 (TDP43) protein aggregates, which drive the pathogenesis of 
amyotrophic lateral sclerosis (ALS) 39. In an IPTG-inducible GFP-TDP43 U2OS 
osteosarcoma cell line model, IPTG stimulation led to the rapid formation of TDP43 
aggregates, which were reduced by 75 % upon 7 hours of EN6 cotreatment (Fig. 4f, 
Supplementary Fig. 4e). EN6-mediated clearance of TDP43 aggregates was lysosome- and 
v-ATPase-dependent, as it was prevented by co-treatment with BafA1 (Fig. 4f, 
Supplementary Fig. 4e). We observed pronounced clearance of TDP43 aggregates in IPTG 
pre-stimulated cells within as little as 4 hours of EN6 treatment, suggesting that the post-
transcriptional actions of EN6 are sufficient to boost cellular clearance (Supplementary Fig. 
4f–4i).
A previous study reported a covalent ligand, that we name CZ (3) here (Supplementary Fig. 
5a), that targets an alternate C138 in human ATP6V1A that reportedly inhibits v-ATPase 
activity 34. We verified that CZ significantly inhibited v-ATPase activity in vitro and in cells, 
albeit to a lesser extend than BafA1, whereas EN6 stimulated v-ATPase activity 
(Supplementary Fig. 5b–5c). Consistent with v-ATPase inhibition and similarly to BafA, CZ 
inhibited LC3b processing and p62 degradation, whereas EN6 stimulated it (Supplementary 
Fig. Fig. 5d–5e). CZ also did not clear TDP43 aggregates (Supplementary Fig. 5f). v-
ATPase inhibition by BafA was previously shown to inhibit mTORC1 and, similarly, CZ 
treatment decreased mTORC1 signaling, as did EN6 (Supplementary Fig. 5g) 18. However, 
consistent with a different mechanism of action, CZ did not alter mTORC1 lysosomal 
localization under amino acid stimulation, whereas EN6 effectively abolished it 
(Supplementary Fig. 5h–5i) 34. Taken together these data demonstrate that, by covalently 
targeting different cysteines within ATP6V1A, EN6 and CZ exert profoundly different 
actions, whereby only EN6 has the desired profile of simultaneous mTORC1 inhibition and 
v-ATPase activation that dramatically boosts cellular clearance.
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EN6 Inhibits mTORC1 and Activates Autophagy In Vivo
We next tested whether EN6 was able to inhibit mTORC1 and activate autophagy in vivo. 
Previous studies have shown that inhibition of mTORC1 signaling improves cardiac and 
skeletal muscle in various disease paradigms, including muscular dystrophy, 
cardiomyopathy, aging, and sarcopenia 40–43. We thus focused our attention on mTORC1 
signaling and autophagy in skeletal muscle and heart. Dose-response and time-course 
studies showed bioavailability of EN6 in skeletal muscle and heart within one hour of 
treating mice with 50 mg/kg intraperitoneal (i.p.) dose (Supplementary Fig. 6a). EN6 
treatment significantly inhibited mTORC1 signaling in both skeletal muscle and heart, as 
demonstrated by reduced phosphorylation of S6, 4EBP1, and ULK1 whereas autophagy was 
strongly activated, as shown by heightened LC3BII levels and reduced p62 levels (Fig. 5a–
5b, Supplementary Fig. 6b). While EN6 was somewhat less potent than rapamycin in 
shutting down p-S6, it was significantly more effective than rapamycin at inhibiting 
phosphorylation of 4EBP1 and ULK1, as well as inducing LC3b cleavage and p62 
degradation, consistent with our data in cell lines (Fig. 5a–5b). We also did not observe 
inhibition of mTORC2-dependent AKT phosphorylation with EN6 treatment (Fig. 5a–5b, 
Supplementary Fig. 6b). While we only tested EN6 effects upon mTORC1 signaling and 
autophagy in skeletal muscle and heart in this study, it will be of future interest to determine 
the effects of EN6 in additional tissues. Thus, due to its unique mechanism of action, EN6 
functions as a complete mTORC1 inhibitor without affecting off-target AKT signaling 
pathways, and induces autophagy and lysosomal degradation both in cells and in vivo.
Discussion
Our study identifies a covalent ligand, EN6, which targets a unique druggable hotspot—
C277 within the v-ATPase subunit ATP6V1A—to activate autophagy by completely 
inhibiting mTORC1 signaling through disrupting mTORC1 localization to the lysosome 
without affecting off-target AKT signaling pathways (Fig. 6). This is a distinct mechanism 
from other pharmacological modulators of autophagy such as with rapalogues and ATP-
competitive inhibitors, which act through directly targeting the kinase function mTORC1. 
While both rapalogues and ATP-competitive mTORC1 inhibitors have potential therapeutic 
activity, their clinical utility is hampered by their incomplete mTORC1 inhibition 
(rapalogues) and concomitant inhibition of mTORC2 (ATP competitors) 44–46. Chronic 
exposure to rapalogues also inhibits mTORC2, leading to metabolic dysregulation 47,48. 
Whereas the effects of long-term EN6 treatment on mTORC2 signaling remain to be 
determined, the ability of EN6 to selectively target an mTORC1-specific activation node 
makes it unlikely that mTORC2 inhibition will occur (Refs 6, 47, 48 here). EN6 shows 
promising cellular and in vivo activity. However, this covalent ligand is an early hit that still 
requires further medicinal chemistry efforts to optimize potency, selectivity, in vivo 
bioavailability and efficacy, and ideally brain penetrance. While we show here that EN6 
inhibits mTORC1 signaling after 4 h of treatment in mice, we do not yet know how long this 
inhibition is sustained in vivo. Since EN6 is irreversibly bound to ATP6V1A, the 
reactivation of ATP6V1A will likely depend on protein turnover rates. Furthermore, while 
isoTOP-ABPP studies here show that C277 of ATP6V1A is one of the primary and most 
highly engaged targets of EN6 in cells, EN6 may possess additional off-targets that either 
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exhibit lower degree of engagement, react with other amino acids, or act through reversible 
interactions that may contribute to EN6 effects on autophagy or trigger additional biological 
effects that need to be determined. Development of an alkyne-functionalized EN6 probe will 
aid in future assessment of EN6 selectivity and provide a foundation for additional 
medicinal chemistry, target engagement, and screening efforts to identify improved ligands 
against this site. Nonetheless, our study convincingly demonstrates that the EN6 effects 
upon mTORC1 signaling and autophagy are driven through the targeting of C277 of 
ATP6V1A.
A key question is how covalent modification of C277 within ATP6V1A affects v-ATPase 
function and mTORC1 regulation. By inspecting the previously reported crystal structures of 
the v-ATPase from Thermus Termophilus and Enterococcus Hirae 49, we note that the 
equivalent residues to human C277, C255 in Thermus and C259 in Enterococcus V1A 
subunits, respectively, lie in the core of the catalytic B-A interface, in close proximity to 
residues that are critical for catalysis, such as E279 in human (E257 in Thermus and E261 in 
Enterococcus, respectively). Because the side chain of C277 points away from the 
nucleotide, this residue is unlikely to directly participate in catalysis. However, covalent 
modification of this cysteine likely results in realignment of nearby residues, leading to 
higher rate of ATP hydrolysis and/or increased coupling between the V1 and V0 domains 
that ultimately accelerates proton pumping and lysosomal acidification 50.
Is the increased v-ATPase catalytic rate related to the observed strong inhibition of mTORC1 
signaling by EN6? A plausible model supported by previous data is that a fraction of the 
energy generated by ATP hydrolysis may be utilized for mTORC1 activation via the 
physical coupling between the v-ATPase and Ragulator-Rags (Fig. 6) 18. Consistent with 
this model, our co-IP data indicate that the conformational change induced by covalent 
modification of C277 partially uncouples the v-ATPase from Ragulator-Rag, making their 
binding insensitive to amino acids and weaker overall.
The physical coupling model proposed here is not in conflict with previous studies where 
blocking the v-ATPase using ConA or BafA results in mTORC1 inhibition 18,26. According 
to this model, mTORC1 activation can be prevented by either BafA-mediated inhibition of 
the v-ATPase catalytic function (such that no energy is generated for Rag regulation) or by 
making this energy unavailable through disrupted interaction between v-ATPase and 
Ragulator-Rags (as in the case of EN6). Future structural biology efforts on reconstituted v-
ATPase-Ragulator-Rag supercomplex will yield additional insights into the mechanism 
through which the v-ATPase enables mTORC1 recruitment to the lysosome, and into how 
covalent modification by EN6 disrupts this process.
A major challenge of chemical genetic screens is identifying the targets of leads that arise 
from screens. The structures lead compounds must often be altered or derivatized to bear 
biorthogonal and photoaffinity handles or conjugated to beads to facilitate chemoproteomic 
target identification. These approaches require additional synthetic efforts to make analogs 
of the lead molecule and alter the structure of the molecule, which may hinder or prevent 
initial target identification efforts. Previous studies have highlighted the utility of covalent 
ligands and ABPP-based approaches in accessing unique ligandable sites within classically 
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undruggable protein targets 31,33. Our study once again highlights the utility of 
chemoproteomics-enabled covalent ligand screening platforms to rapidly deconvolute the 
mechanism of action of cellular phenotypic screening hits and uncover unique and novel 
ligandable sites and druggable modalities that would not be predicted a priori. In this study, 
we reveal a cell and in vivo-active covalent ligand EN6 that uniquely targets a novel 
ligandable cysteine within the ATP6V1A component of the v-ATPase complex to inhibit 
mTORC1 signaling and activate autophagy to improve cellular clearance.
Online Methods
Cell Culture
Human embryonic kidney HEK293T and HEK293A cells, mouse embryonic fibroblasts 
(MEF), HeLa cells, HEK293A cells stably expressing GFP-LC3-RFP-LC3ΔG (plasmid 
purchased from Addgene), MEF cells stably expressing GFP-LC3-RFP-LC3ΔG (plasmid 
purchased from Addgene) and human bone osteosarcoma epithelial U2OS cells stably 
expressing an IPTG-inducible GFP-TDP43 were maintained in DMEM supplemented with 
10 vol% FBS and 1 vol% GlutaMax. GFP-TDP43 cell lines were purchased from Innoprot 
(P30710). All cells were incubated in 5% CO2 humidified air, and subcultured when 80% 
confluence was reached. They were free of mycoplasma contamination, and routinely 
checked using MycoAlert Mycoplasma Detection Kit (Lonza, LT07–318) and DAPI 
staining.
Screening for autophagy modulators
MEF cells stably expressing GFP-LC3-RFP-LC3ΔG were plated on 96-well plates 
(Corning; 3904) at 30,000 cells/well and allowed to grow in complete medium overnight. 
The cells were then incubated with covalent ligands (50 μM or at indicated concentrations), 
rapamycin (100 nM), Torin 1 (250 nM) or DMSO solvent control in complete medium (100 
μL) for 24 h. After that, the medium was aspirated and the cells were fixed with 4% 
paraformaldehyde in PBS (100 μL) for 10 min, washed with PBS (100 μL) and assayed in 
PBS (100 μL) by SpectraMax i3 (Molecular Devices). GFP fluorescence was measured with 
excitation and emission at 488±9 nm and 514±15 nm respectively, while RFP fluorescence 
was measured with excitation and emission at 584±9 nm and 612±15 nm respectively.
For HEK293A cells stably expressing GFP-LC3-RFP-LC3ΔG, before they were seeded, 96-
well plates were coated with fibronectin in PBS (5 μg/mL, 75 μL/well) for 1 h at 37 °C. The 
solution was then aspirated, and cells were plated at 30,000 cells/well, allowed to grow in 
complete medium overnight, treated and assayed with the same protocol as described above 
for MEF cells.
For checking cell viability, solutions were aspirated after treatment with the compounds, and 
the cells were fixed and stained by Hoechst 33342 (13.3 μg/mL) in formalin (100 μL) for 15 
min. After that, cells were washed with PBS (100 μL) and assayed in PBS (100 μL) by 
SpectraMax i3 with excitation and emission at 350±9 nm and 461±15 nm respectively.
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Transmission electron microscopy
HEK293A cells grown on tissue culture plates were fixed in 2.5% glutaraldehyde 0.1 M 
sodium cacodylate buffer, pH 7.4 (EMS, Hatfield, PA, USA) for 30 min at room temperature 
and then gently scraped using a rubber policeman. Cell pellets were stabilized in 1% low 
melting point agarose, then cut into 1mm cubes. Samples were rinsed (3x; 10 min, room 
temperature) in 0.1 M sodium cacodylate buffer, pH 7.2, and immersed in 1 % osmium 
tetroxide with 1.6 % potassium ferricyanide in 0.1 M sodium cacodylate buffer for 1 hour. 
Samples were rinsed (3x; 10 min, room temperature) in buffer and then in distilled water 
(3x; 10 min, room temperature). Sample were immersed in 0.5 % aqueous uranyl acetate en 
bloc stain for 1 hour, protected from light and then rinsed in water (3x; 10 min, room 
temperature). Samples were then subjected to an ascending acetone gradient (10 min; 35 %, 
50 %, 70 %, 80 %, 90 %) followed by pure acetone (2x; 10 min, room temperature). 
Samples were progressively infiltrated while rocking with Epon resin (EMS, Hatfield, PA, 
USA) and polymerized at 60 °C for 24–48 hours. Thin sections (70 nm) were cut using a 
Reichert Ultracut E (Leica, Wetzlar, Germany). Sections were then collected onto formvar-
coated 200 mesh copper grids. The grids were post-stained with 2 % uranyl acetate followed 
by Reynold’s lead citrate, for 5 min each. The sections were imaged using a Tecnai 12 
120kV TEM (FEI, Hillsboro, OR, USA) and data recorded using an UltraScan 1000 with 
Digital Micrograph 3 software (Gatan Inc., Pleasanton, CA, USA).
IsoTOP-ABPP chemoproteomic studies
IsoTOP-ABPP studies were done as previously reported 30,31. Briefly, cells were lysed by 
probe sonication in PBS and protein concentrations were asessed by BCA assay 51. Cells 
were then treated for 90 min with either DMSO vehicle or EN6 (from 1000X DMSO stock). 
Proteomes were subsequently labeled with IA-alkyne labeling (100 μM) for 1 h at room 
temperature. CuAAC was used by addition sequentially of tris(2-carboxyethyl)phosphine (1 
mM, Sigma), tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (34 μM, Sigma), copper (II) 
sulfate (1 mM, Sigma), and biotin-linker-azide—the linker functionalized with a TEV 
protease recognition sequence as well as an isotopically light or heavy valine for treatment 
of control or treated proteome, respectively. After CuAAC, proteomes were precipitated, 
washed in ice-cold methanol, combined in a 1:1 control/treated ratio and washed again. The 
protein pellet was then denatured and resolubilized by heating in 1.2% SDS/PBS to 80 °C. 
Insoluble components were precipitated by centrifugation at 6500 x g and soluble proteome 
was diluted in 5 ml 0.2% SDS/PBS. Labeled proteins were enriched using avidin-agarose 
beads (Thermo Pierce) by overnight rotating at 4 °C. Enriched proteins were washed on-
bead three times in PBS and water. Samples were then resuspended in 6 M urea/PBS 
(Sigma) and subjected to TCEP reduction (1 mM, Sigma), iodoacetamide (IA) alkylation 
(18 mM, Sigma), and then washed and resuspended in 2 M urea and subjected to trypsin 
digestion overnight with sequencing grade trypsin (Promega). Tryptic peptides were eluted 
off and beads were subsequently washed three times each in PBS and water, washed in TEV 
buffer solution (water, TEV buffer, 100 μM dithiothreitol) and resuspended in buffer with 
Ac-TEV protease and incubated overnight. Peptides were diluted in water and acidified with 
formic acid (1.2 M, Spectrum) and prepared for analysis.
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Mass Spectrometry Analysis
Mass spectrometry analysis was performed as previously described 30,31. Briefly, peptides 
were pressure-loaded onto a 250 μm inner diameter fused silica capillary tubing packed with 
4 cm of Aqua C18 reverse-phase resin (Phenomenex #04A-4299) which was previously 
equilibrated. The samples were then attached using a MicroTee PEEK 360 μm fitting 
(Thermo Fisher Scientific #p-888) to a 13 cm laser pulled column packed with 10 cm Aqua 
C18 reverse-phase resin and 3 cm of strong-cation exchange resin for isoTOP-ABPP studies. 
Samples were analyzed using an Q Exactive Plus mass spectrometer (Thermo Fisher 
Scientific) using a 5-step Multidimensional Protein Identification Technology (MudPIT) 
program. One full MS (MS1) scan (400–1800 m/z) was followed by 15 MS2 scans (ITMS) 
of the nth most abundant ions. Heated capillary temperature was set to 200 °C and the 
nanospray voltage was set to 2.75 kV.
Data was searched against the Uniprot mouse database using ProLuCID search methodology 
in IP2 v.3 (Integrated Proteomics Applications, Inc) 52. Cysteine residues were searched 
with a static modification for carboxyaminomethylation (+57.02146) and up to two 
differential modifications for methionine oxidation and either the light or heavy TEV tags 
(+464.28596 or +470.29977, respectively). Only fully tryptic peptides were analyzed. 
ProLuCID data was filtered through DTASelect to achieve a peptide false-positive rate 
below 5%. Only those probe-modified peptides that were evident across two out of three 
biologically independent groups were interpreted for their isotopic light to heavy ratios. 
Those probe-modified peptides that showed ratios >2.5 were further analyzed as potential 
targets of the covalently-acting small-molecule. For modified peptides with ratios >2.5, we 
only interpreted peptides that were found across all three biological replicates, showed p-
values<0.03, and showed high quality MS1 peak shapes across the biological replicates. 
Light versus heavy isotopic probe-modified peptide ratios are calculated by taking the mean 
of the ratios of each replicate paired light compared to heavy precursor abundance for all 
peptide spectral matches (PSM) associated with a peptide. Ratios that were “infinite” or 
>1000 due to no corresponding heavy or light signal or those ratios <0.001 were replaced 
with the median ratio of the remaining ratio values. The paired abundances were also used to 
calculate a paired sample t-test p-value in an effort to estimate constancy within paired 
abundances and significance in change between treatment and control. P-values were 
corrected using the Benjamini/Hochberg method.
Constructing knockdown lines
We used short-hairpin oligonucleotides to knock down the expression of ATP6V1A in Hela 
cells using previously described methods 53. The pLKO.1 lentiviral vector (TRC, Broad 
institute) was used to express the shRNA against ATP6V1A (TRCN0000029542). 
ATP6V1A WT or C277A or C277S resistant to the shRNA was cloned into pLKO.1 shRNA 
vector under the hPGK promoter. For lentivirus production, lentiviral plasmids and 
packaging plasmids (pMD2.5G, Addgene #12259 and psPAX2, Addgene #12260) were 
transfected into HEK293T cells using PEI transfection method. Viral supernatant was 
collected 48 hours after transfection and filtered with 0.45 μm filter. The viruses were further 
concentrated using Lenti-X Concentrator (Clontech, 631231) according to the 
manufacturer’s instructions. Target cells were plated in 6-well or 10 cm plates with 8 μg/mL 
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polybrene (Millipore, TR-1003-G) and incubated with virus containing media. 24 hours 
later, the media was changed to fresh media containing 2 μg/mL puromycin (Calbiochem, 
540411) and selected for over 3 days. Knockdown and protein expression were confirmed by 
immunoblotting.
Gel-Based ABPP
Gel-based ABPP methods were performed as previously described 31,54–56. Pure human 
ATP6V1A protein was purchased from Abcam (ab132441). Pure protein (0.1 μg) was pre-
treated with DMSO vehicle or covalent ligand for 1 h at 37 °C in 50 μL PBS, and were then 
treated with tetramethylrhodamine-5-iodoacetamide dihydroiodide (IA-rhodamine; 1 μM 
final concentration) for 1 h at room temperature. Samples were quenched with 4 x reducing 
Laemmli SDS sample loading buffer (Alfa Aesar) and heated at 90 °C for 5 min. Samples 
were then separated by molecular weight on precast 4–20% TGX gels (Bio-Rad 
Laboratories, Inc.) and scanned by ChemiDoc MP (Bio-Rad Laboratories, Inc). Target 
labeling was quantified by densitometry with ImageJ.
Resynthesis and characterization of EN6
The initial autophagy screen shown in Fig. 1A used EN6 from our screening plates. All 
subsequent uses of EN6 in this study are either from resupplied EN6 or resynthesized EN6. 
Repurchased EN6 was >97 % purity. See supporting information for experimental details.
Covalent Ligand Library
Synthesis and characterization data of cysteine non-reactive EN6 analog, CC2–49, can be 
found in Supporting information. Synthesis and characterization of other covalent ligands 
screened here have been previously reported and were >95 % purity 28–31,57,58. Compounds 
that begin with “EN” were obtained from Enamine LLC and were of at least 90 % purity.
Antibodies and reagents for biological experiments
Antibodies to phospho-T389-S6K1 (9234), S6K1 (2708), phospho-S65–4E-BP1(9451), 
phospho-T37/46 4E-BP1 (2855), 4E-BP1 (9644), phospho-T308-Akt (13038), phospho-
S473-Akt (4060), Akt (4691), phospho-S757-ULK1 (14202), ULK1 (8054), S6 (9202), 
phospho-S240/244 S6 (5364), LC3B (3868), p62/SQSTM1 (39749), ATP6V1B2 (14617), 
and FLAG epitope (2368) were from Cell Signaling Technology; Antibody to ATP6V1A 
(ab137574) was from Abcam; Antibodies to LAMP2 (sc-18822), GFP (sc-9996) and 
ATP6V1D (sc-390164) were from Santa Cruz Biotechnology. Goat anti-rabbit IgG 
superclonal secondary antibody-Alexa Fluor 647 (A27040) and anti-mouse IgG superclonal 
secondary antibody-Alexa Fluor 488 (A228175) were from Thermo Fisher Scientific. 
IRDye® 800CW Goat anti-Rabbit IgG (H + L; 926–32211) was from Li-Cor. Recombinant 
human ATP6V1A protein (ab132441) was from Abcam; Tetramethylrhodamine-5-
iodoacetamide dihydroiodide (6222) was from Setareh Biotech.; Normal goat serum (10%; 
50062Z), Hoechst 33342 (H3570) and LysoSensor Yellow/Blue DND-160 (L7545) were 
from Thermo Fisher Scientific. Amino acids, Flag-M2 affinity gel (A2220) and Bafilomycin 
A1 (B1793) from Sigma-Aldrich. Torin 1 (4247) from Tocris Biosciences. Rapamycin was 
from Selleckchem. Pierce Protease Inhibitor Tablets (A32965) from Thermo Fisher 
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Scientific. Amino acid-free RPMI (R9010–01) from US Biologicals. Dulbecco’s Modified 
Eagle’s Medium (DMEM; 10–013-CV) and fetal bovine serum (FBS; 35–015-CV) were 
from Corning. 0.25% Trypsin-EDTA (1×; 25200–056) and GluatMax (100×; 25030–081) 
were from Thermo Fisher Scientific. Sequencing grade modified trypsin (V51111) was from 
Promega.
Amino acid starvation and stimulation
Sub-confluent cells were rinsed and incubated with RPMI without amino acids 
supplemented with 2% dialyzed FBS for 50 min, as described 20. Stimulation with amino 
acids (concentration as in RPMI) was performed for 10 min. Where drug treatment was 
performed, cells were incubated during the 50 min starvation period and the 10 min 
stimulation period.
Western blotting and immunoprecipitation
Cells were washed twice with ice-cold phosphate-buffered saline (PBS) and lysed in lysis 
buffer (1% Triton X-100, 10 mM β-glycerol phosphate, 10 mM sodium pyrophosphate, 4 
mM EDTA, 40 mM HEPES at pH 7.4, and 1 tablet of EDTA-free protease inhibitors per 50 
ml). Cell lysates were cleared by centrifugation in a microcentrifuge at 17,000 x g for 10 
minutes at 4 °C. Cell lysate samples were prepared by addition of 5X sample buffer, heated 
at 95 °C for 5 minutes, resolved by 10% or 12% SDS-PAGE, and analyzed by 
immunoblotting. Antibodies were obtained from various commercial sources and dilutions 
were prepared per recommended manufacturers’ procedures.
For FLAG immunoprecipitations, HEK293T cells stably expressing Flag-tagged proteins 
were lysed as above and 30 μL of a well-mixed 50% slurry of anti-FLAG M2 Affinity Gel 
(Sigma A2220) was added to each lysate (1 mg/ml) and incubated at 4 °C in a shaker for 1 
hour. Immunoprecipitates were washed four times, three times with lysis buffer and once 
with lysis buffer containing 400 mM NaCl. Immunoprecipitated proteins were denatured by 
addition of 50 μL of sample buffer and heating to 95 °C for 5 minutes, resolved by SDS-
PAGE, and analyzed by immunoblotting.
Imaging LC3B puncta in EN6-treated HEK293A cells by confocal fluorescence microscopy
HEK293A cells were plated on fibronectin-coated (5 μg/mL) 8-well Lab Tek borosilicate 
chambered coverglass slides (Nunc) at 40,000 cells/well and allowed to grow in complete 
medium overnight. The cells were then incubated with EN6 (at indicated concentrations), 
Torin 1 (250 nM) or DMSO control for indicated time intervals. After aspiration of the 
solution, the cells were washed with PBS (350 μL) and fixed with methanol for 15 min at 
−20 °C. The cells were rinsed three times with PBS (350 μL each), and incubated with PBS 
containing 5% normal goat serum and 0.3% Triton X-100 (300 μL) for 1 h. The cells were 
washed with PBS (350 μL) and incubated with anti-LC3B (Cell Signaling Technology 
#3868; v/v, 1:200) in PBS containing 1% BSA and 0.3%Triton X-100 at 4 °C overnight. 
After that, the cells were washed three times with PBS (350 μL each), and incubated with 
anti-rabbit superclonal secondary antibody-Alexa Fluor 647 (Thermo Fisher Scientific 
A27040; v/v = 1:500) in PBS containing 1% BSA and 0.3%Triton X-100 in dark at room 
temperature for 1 h. The cells were washed three times with PBS (350 μL each) and stained 
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with Hoechst 33342 (5 μg/mL) in PBS in dark at room temperature for 15 min. After 
washing with PBS three times (350 μL each), the cells were imaged in PBS by Zeiss laser 
scanning microscope (LSM) 710 with a 20× or 63× oil-immersion objective lens. Hoechst 
33342 was excited with a 405 nm diode laser, and emission was collected on a META 
detector between 410 and 587 nm. Alexa Fluor 647 was excited with a 633 nm HeNe laser, 
and emission was collected on a META detector between 638 and 755 nm.
Image analysis was performed by use of ImageJ. A threshold of 100–255 (for 8-bit images) 
was first set for selection of LC3B puncta, and a region of interest (ROI) was created over a 
single cell. The number of cellular LC3B puncta was then quantified by “Analyze Particles” 
using size and circularity of 0.1–infinity and 0.0–1.0 respectively. 25 individual cells of each 
group from triplicate experiments were analyzed, and the statistical analyses were performed 
with a two-tailed Student’s t-test (MS Excel).
Imaging TFEB cellular localization
Hela cells stably expressing TFEB-GFP were seeded on glass coverslips coated with 
fibronectin and incubated for 24hrs. After incubation, cells were treated with either DMSO 
or EN6 for 4 hours, fixed for 10 min with 4% paraformaldehyde (PFA) and were 
subsequently mounted on slides using Vectashield. Images were taken using a Nikon Eclipse 
Ti microscope with Andor Zyla-4.5 sCMOS camera, as mentioned above. 5 different fields 
were acquired per condition and TFEB localization were assessed.
Imaging lysosomal recruitment of mTORC1 by immunofluorescence
HEK293T or Hela cells were seeded on fibronectin-coated glass coverslips and allowed to 
attach overnight. On the following day, cells were subjected to either amino acid starvation 
and stimulation with or without drug incubation and fixed in 4% paraformaldehyde (PFA) 
for 15 minutes at room temperature. The coverslips were rinsed twice with PBS and cells 
were permeabilized with 0.1% (w/v) saponin in PBS for 10 minutes. After rinsing twice 
with PBS, the slides were incubated with primary antibodies in 5% normal donkey serum 
(Jackson ImmunoResearch, 017-000-121) for 1 hour at room temperature, rinsed four times 
with PBS, and fluorophore conjugated secondary antibodies derived from goat or donkey 
(Life Technologies, diluted 1:400 in 5% normal donkey serum) were incubated for 1 hour at 
room temperature in the dark. The coverslips were then washed four times with PBS, 
mounted on glass slides using Vectashield (Vector Laboratories) and imaged on a spinning 
disk confocal system built upon a Nikon Eclipse Ti microscope with Andor Zyla-4.5 
sCMOS camera.
Imaging lysosomal pH by LysoSensor DND-160
HEK293A cells were plated on fibronectin-coated (5 μg/mL) 12 mm glass based dishes 
(Nunc) at 1,000,000 cells/well and allowed to grow in complete medium overnight. The cells 
were then incubated with DMSO control, EN6 (50 μM), bafilomycin A1 (0.2 μM), or a 
mixture of EN6 and bafilomycin A1 (50 and 0.2 μM respectively) at 37 °C for 4 h. After 
that, LysoSensor DND-160 (2 μM final concentration) was added to the solution and the 
cells were stained at 37 °C for 5 min. The solution was then replaced by DPBS and the live 
cells were imaged by Zeiss LSM 880 with a 40× water-immersion objective lens. The blue 
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fluorescence of DND-160, Fblue, was excited with a two-photon laser at 730 nm and 
emission was collected on a META detector between 400 and 490 nm. The yellow 
fluorescence of DND-160, Fyellow, was excited with a two-photon laser at 730 nm and 
emission was collected on a META detector between 514 and 649 nm.
For converting Fyellow / Fblue to pHs, a pH calibration curve was constructed from HEK293A 
cells stained with DND-160 (2 μM) in DPBS at 37 °C for 5 min, washed by PBS, incubated 
with different pH buffer solutions (pH 3.5, 4.5, 5.0 and 5.5) in the presence of Valinomycin 
(10 μM) and Nigericin (10 μM) at 37 °C for 5 min, and imaged by LSM 880 with two-
photon excitation at 730 nm and emissions collected at 400–490 nm and 514–649 nm for 
Fblue and Fyellow respectively.
The ratiometric images, Fyellow / Fblue, were generated by Ratio Plus plugin of ImageJ. For 
quantification, a threshold value was set as background and the average intensity of the 
whole image was measured by ImageJ. All experiments were performed in triplicate, and 
statistical analyses were performed with a two-tailed Student’s t-test (MS excel).
In vitro v-ATPase assays
The experiment was performed as previously described 18. In brief, two 15cm confluent 
HEK293T cells were incubated overnight with 30 μg/ml 70 kDa Dextran conjugated to 
Oregon Green 514 (Dx-OG514, Invitrogen). The next day, cells were washed and chased for 
2 hours in serum free DMEM to allow lysosomal accumulation of Dx-OG514. 15 minutes 
prior to lysis, 1 μM FCCP was added to dissipate the lysosomal pH gradient. Cell were then 
harvested and mechanically broken using a 23 G needle in fractional buffer: 140 mM KCl, 1 
mM EGTA, 20 mM HEPES, 50 mM Sucrose (pH 7.4), supplemented with 5 mM Glucose, 
protease inhibitor and 1 μM FCCP. Lysed cells were spun down at 1700 rpm for 10 min at 
4°C and the supernatant was collected. The resulting post-nuclear supernatant (PNS) was 
spun down at max speed at 4°C, yielding a pellet containing the organellar fraction. Each 
fraction was resuspended in 180 μl of fractionation buffer devoid of FCCP and transferred to 
a 96-multiwell (black). Baseline fluorescence was collected at 530 nm upon 490 nm 
excitation in SpectraMax i3 at 30sec intervals for 5 min. Various compounds were added to 
each well followed by 5 mM ATP and MgCl2, and fluorescence reading was resumed for 
further 45 min. The fluorescence emission of Dx-OG514 decayed exponentially over time 
due to the lysosomal reacidification of the v-ATPase.
RNA extraction and quantitative RT-PCR (qRT-PCR)
Total RNAs were extracted using Aurum™ Total RNA Mini Kit (Bio-rad) and reverse 
transcription was performed from 1 μg total RNAs using iScript™ Reverse Transcription for 
RT-qPCR (Bio-rad) according to manufacturer’s instruction. All real-time qPCR (qRT-PCR) 
analyses were performed using StepOnePlus machine (Applied Biosystems) with 
SsoAdbanced™ Universal SYBR Green supermix (Bio-rad).
The quantity of mRNA was calculated using the ΔΔCt method and normalized to β-actin. 
All reactions were performed as triplicates.
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Assessing TDP-43 aggregates
U2OS cells stably expressing an IPTG-inducible GFP-TDP-43 (Innoprot) were plated on 
fibronectin-coated (5 μg/mL) 8-well Lab Tek borosilicate chambered coverglass slides 
(Nunc) at 30,000 cells/well and allowed to grow in complete medium overnight. For co-
incubation experiments, the cells were incubated with DMSO control, isopropylthio-β-
galactoside (IPTG; 50 μM), a mixture of EN6 (25 μM) and IPTG (50 μM), or a mixture of 
EN6 (25 μM), IPTG (50 μM) and bafilomycin A1 (0.2 μM) at 37 °C for 7 h. The cells were 
washed with PBS (350 μL) and fixed with 4% paraformaldehyde (PFA) for 15 minutes at 
room temperature. After fixation, the cells were washed three times with PBS (350 μL each) 
and stained with Hoechst 33342 (0.5 μg/mL) in PBS in dark at room temperature for 15 min. 
After washing with PBS three times (350 μL each), the cells were imaged in PBS by Zeiss 
laser scanning microscope (LSM) 710 with a 20× or 63× oil-immersion objective lens. 
Hoechst 33342 was excited with a 405 nm diode laser, and emission was collected on a 
META detector between 410 and 483 nm. GFP was excited with a 488 nm Ar laser, and 
emission was collected on a META detector between 493 and 598 nm.
For pre-stimulation experiments, U2OS cells stably expressing an IPTG-inducible GFP-
TDP-43 were pre-treated with IPTG (1 mM) at 37 °C for 4 h to express GFP-TDP-43 
aggregates. Then, the cells were treated with DMSO control or EN6 (25 μM) at 37 °C for 4 
h. The treated cells were washed, fixed and imaged as described above for visualizing 
TDP-43 aggregates by GFP fluorescence. For visualizing TDP-43 aggregates by anti-GFP 
immunofluorescence, cells after treatment with DMSO and EN6 were washed with PBS 
(350 μL) and fixed with 4% paraformaldehyde (PFA) for 15 minutes at room temperature. 
After fixation, the cells were washed three times with PBS (350 μL each), incubated with 
PBS containing 1% BSA and 0.3% Triton X-100 at room temperature for 1 h, and incubated 
with mouse anti-GFP (sc-9996; 1:100 dilution) in PBS containing 1% BSA and 0.3% Triton 
X-100 at 4 °C overnight. Then, the cells were washed with PBS containing 1% BSA and 
0.3% Triton X-100 three times, and incubated with anti-mouse IgG superclonal secondary 
antibody-Alexa Fluor 488 (A228175; 1:500 dilution) in PBS containing 1% BSA and 0.3% 
Triton X-100 at room temperature for 1 h. After washing with PBS containing 1% BSA and 
0.3% Triton X-100 three times, the cells were stained with Hoechst 33342 (0.5 μg/mL) in 
PBS in dark at room temperature for 15 min, washing with PBS three times and imaged in 
PBS by Zeiss laser scanning microscope (LSM) 710 with a 20× or 63× oil-immersion 
objective lens. Hoechst 33342 was excited with a 405 nm diode laser, and emission was 
collected on a META detector between 410 and 483 nm. Anti-GFP immunofluorescence was 
collected on a META detector between 493 and 630 nm with excitation at 488 nm by Ar 
laser.
Image analysis was performed by use of ImageJ. A threshold was first set for selection of 
GFP-TDP-43 aggregate, and a region of interest (ROI) was created over a single cell. The 
number of cellular aggregates was then quantified by “Analyze Particles” using size and 
circularity of 0.3–infinity and 0.0–1.0 respectively. 26 individual cells of each group from 
triplicate experiments were analyzed, and the statistical analyses were performed with a two-
tailed Student’s t-test (MS Excel).
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Assessing mTORC1 inhibition in vivo and pharmacokinetics of EN6 in mice
6-week-old male C57BL/6 mice (Jackson Laboratory) were injected intraperitoneally with 
solvent control, EN6 (50 mg/kg) or rapamycin (10 mg/kg) in saline/ethanol/PEG-40 (v/v/v = 
18:1:1). After 4 h, mice were euthanized, and tissues were harvested and lysed in lysis buffer 
(1% Triton X-100, 10 mM β-glycerol phosphate, 10 mM sodium pyrophosphate, 4 mM 
EDTA, 40 mM HEPES at pH 7.4, and 1 tablet of EDTA-free protease inhibitors per 50 ml) 
at 4 °C for 30 min. The lysates were cleared by centrifugation in a microcentrifuge at 21,130 
g for 10 minutes at 4 °C and protein concentration of supernatant was determined by BCA 
assay (Thermo Fisher Scientific). The lysates were then diluted to 1.5 mg/mL, mixed with 
4× sample buffer, heated at 95 °C for 5 minutes, resolved by precast 4–20% TGX gels, and 
analyzed by immunoblotting. Antibodies were obtained from various commercial sources 
and dilutions were prepared per recommended manufacturers’ procedures.
For pharmacokinetics studies, mice were injected intraperitoneally with solvent control or 
EN6 at indicated doses. At indicated time intervals, mice were euthanized, and tissues were 
harvested. The tissues were then weighed and homogenized, and EN6 was extracted from 
chloroform:methanol:PBS solution mixture (2:1:1, v/v/v; 4 mL total) with dodecylglycerol 
(10 nmol) as internal standard. The organic layer was collected, evaporated under stream of 
N2, re-dispersed in chloroform and analyzed by multiple-reaction monitoring (MRM)-based 
targeted LC-MS/MS on an Agilent 6430 QQQ using a Luna reverse phase C5 column (50 
mm × 4.6 mm with 5 mm diameter particles, Phenomenex). Mobile phases: Buffer A, 95:5 
water / methanol; Buffer B: 60:35:5 2-propanol / methanol / water, both with 0.1 % formic 
acid and 50 mM ammonium formate additives. Flow rate began at 0.2 mL/min for 2 min, 
followed by a gradient starting at 0 % B and increasing linearly to 100 % B over the course 
of 23 min with a flow rate of 0.4 mL/min, followed by an isocratic gradient of 100 % B for 5 
min with a flow rate increasing linearly from 0.04 mL/min to 0.4 mL/min. MS analysis was 
performed using electrospray ionization (ESI) with a drying gas temperature of 350 °C, 
drying gas flow rate of 10 L/min, nebulizer pressure 35 psi, capillary voltage 3.0 kV, and 
fragmentor voltage 100 V. Parent/daughter ion MRM transitions used to determine EN6 
levels were 369.34/163.2 and 369.34/189 with fragmentor voltage of 10 and 20, and 30 and 
40, respectively. Peak area of EN6 to that of dodecylglycerol was calibrated to amount of 
EN6 per gram of tissues by LC-MS/MS analysis of a set of solution mixtures containing 
dodecylglycerol (10 nmol) and known concentrations of EN6 (0.01, 0.1, 1, 10 and 30 nmol). 
Data was analyzed using Agilent Qualitative Analysis software by calculating area under the 
curve.
All animal experiments were conducted in accordance with the guidelines of the 
Institutional Animal Care and Use Committees of the University of California, Berkeley.
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Figure 1. Covalent ligand screen for autophagy activators.
(a) Testing autophagy activator hits from covalent ligand screen in MEF cells. HEK293A 
cells expressing a fluorescent probe GFP-LC3-RFP-LC3ΔG to measure autophagic flux, 
were treated with vehicle DMSO or a covalent ligand (50 μM) for 24 h and GFP/RFP ratios 
were analyzed. Compounds that showed significantly (p<0.05 compared to vehicle-treated 
controls) lower GFP/RFP ratios in MEF cells were screened in HEK293A cells expressing 
the same fluorescent autophagic flux probe. Shown in gray are mTORC1 inhibitors Torin1 
and rapamycin and shown in red is the EN6 hit. (b) Structure of cysteine-reactive covalent 
ligand hit EN6 that shows autophagy activation in both MEF and HEK293A cells. (c) Dose-
response of EN6 in HEK293A cells expressing the fluorescent autophagic flux probe. (d) 
LC3B levels in HEK293A cells treated with EN6 (50 μM). Shown is a representative gel 
from n=3 biologically independent samples/group. Original gel images can be found in 
Supplementary Fig. 7a. (e) LC3B puncta in HEK293A cells treated with vehicle DMSO, 
EN6 (50 μM), or Torin1 (0.25 μM). Scale bar shown in (e) denotes 10 μm. Data shown in (a, 
c) are average ± sem, n=3 biologically independent samples/group, and data shown in (e) are 
average ± sem, n=25 individual cells from 3 biologically independent samples/group. 
Statistical significance was calculated with unpaired two-tailed Student’s t-tests. 
Significance is expressed as *p=0.0022, 0.0069, 0.00283, 0.027, 0.0495 for Torin1, EN6, 
DKM 3–16, rapamycin, and EN2, respectively, compared to vehicle-treated controls in (a); 
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*p=0.0064, 0.0037, 0.0037, 0.0069, and 0.018 for 63, 31, 16, 8, 4 μM EN6, respectively, 
compared to vehicle-treated controls in (b); *p=1.1×10−6, 4.2×10e−13, 6.4×10−16 for 1, 4, 8 
h EN6 treatment and *p=2.1×10−12, 8.1×10−16, 1.5×10−8 for 1, 4, 8 h Torin1 treatment, 
respectively, compared to vehicle-treated control groups.
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Figure 2. Target identification and validation of EN6.
(a) isoTOP-ABPP analysis of EN6 in MEF cells in situ. MEF cells were pre-treated with 
DMSO or EN6 (50 μM, 4 h in situ) prior to labeling of proteomes in vitro with IA-alkyne 
(100 μM, 1 h), followed by appendage of isotopically light (for DMSO-treated) or heavy (for 
EN6-treated) TEV protease cleavable biotin-azide tags by copper-catalyzed azide-alkyne 
cycloaddition (CuAAC), followed by the isoTOP-ABPP procedure. Shown are average light/
heavy ratios for n=3 biologically independent samples/group. More detailed data and 
individual replicate ratios can be found in Supplementary Dataset 2. (b) Gel-based ABPP 
analysis of EN6 interactions with recombinant ATP6V1A. Vehicle DMSO or EN6 were pre-
incubated with recombinant human ATP6V1A (1 h) followed by labeling with a rhodamine-
functionalized iodoacetamide probe (IA-rhodamine) (1 μM, 1 h) after which probe-labeled 
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proteins were read-out by SDS/PAGE and in-gel fluorescence. Data were quantified by 
densitometry using Image J. Original gel images can be found in Supplementary Fig. 8a. (c) 
mTORC1 signaling with EN6 treatment in HEK293A cells. HEK293A cells, starved or 
stimulated with amino acids, were treated with vehicle DMSO or EN6 (25 μM) for 1 h and 
mTORC1 signaling was assessed by Western blotting. Original gel images are in 
Supplementary Fig. 7b. (d) Autophagy markers (LC3 and p62) and mTORC1 signaling in 
Hela cells treated with EN6. Endogenous ATP6V1A was knocked down with shRNA and 
replaced with a Flag-tagged wild-type or C277A mutant ATP6V1A and these cells were 
treated with EN6 (25 μM) for 4 h. Original gel images can be found in Supplementary Fig. 
8b. Validation of ATP6V1A knockdown can be found in Supplementary Fig. 2e. Data shown 
in (b) are average ± sem from n=3 biologically independent samples/group. Gels shown in 
(b, c, d) are representative gels from n=3 biologically independent samples/group.
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Figure 3. EN6 inhibits mTORC1 recruitment to the lysosome.
(a) mTORC1 signaling in HEK293T cells expressing either control empty vector or Flag-
tagged RagBQ99L constitutively active mutant protein. Cells were starved of amino acids or 
starved and stimulated with amino acids, in the presence of DMSO vehicle or EN6 for (25 
μM) for 4 h. Original gel images are in Supplementary Fig. 9a. (b) mTORC1 signaling in 
NPRL3 control and knockout HEK293T cells, starved or starved and stimulated with amino 
acids, in the presence of DMSO vehicle or EN6 for (25 μM) for 4 h. Original gel images are 
in Supplementary Fig. 9b. (c) mTORC1 localization in HEK293T cells expressing either 
control empty vector or RagBQ99L constitutively active mutant protein with vehicle DMSO 
or EN6 (25 μM) for 1 h under amino acid starvation or stimulation. Shown are representative 
microscopy images of mTORC1 or the lysosomal marker LAMP2. Scale bar in (c) denotes 
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10 μm. (d) Quantification of mTORC1 lysosomal localization in (c). Data are shown as 
average ± sem from n=5 biologically independent samples/group. Statistical significance 
was calculated with unpaired two-tailed Student’s t-tests. Significance is expressed as 
*p=7.9×10−6 in (d) compared to amino acid-stimulated vehicle-treated control. (e) Co-
immunoprecipitation experiments between stably expressed, FLAG-tagged Ragulator 
subunit p14 and endogenous v-ATPase components in HEK293T cells, in the absence or 
presence of amino acids treated with vehicle DMSO or EN6 (25 μM) for 1 h. Original gel 
images are in Supplementary Fig. 10. Blots shown are representative gels from n=2 in (a, b) 
and n=3 in (e) biologically independent samples/group.
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Figure 4. EN6 effects on TFEB, lysosomal acidification, and clearance of TDP-43 aggregates.
(a) Localization of TFEB-GFP in Hela cells treated with vehicle DMSO or EN6 (25 μM, 4 
h). Cells were stained with Hoechst 33342 (blue) and GFP-TFEB (green) were imaged by 
microscopy. Shown are representative microscopy images and quantification of percentage 
of nuclear TFEB from n=6 and 7 biologically independent samples/group for vehicle-treated 
and EN6-treated groups, respectively. Scale bar in (a) denotes 10 μm. (b) Gene expression of 
TFEB target genes in Hela cells treated with EN6 (25 μM) for 0 or 8 h, assessed by qRT-
PCR from n=3 biologically independent samples/group. (c) Lysosomal acidification of 
HEK293A cells treated with vehicle DMSO, bafilomycin A1 (0.2 μM), EN6 (50 μM), or 
with co-treatment of EN6 and bafilomycin A1 for 4 h, readout by LysoSensor DND-160. 
Microscopy images shown in (c) are representative images from n=3 biologically 
independent samples/group. Scale bar in (c) denotes 40 μm. (d) Quantification of lysosomal 
acidification from experiment described in (c), expressed as average pH of acidic 
compartments. pH calibration curve can be found in Supplementary Fig. 4d. (e) In vitro v-
ATPase activity measurement. Organellar fraction containing lysosomes loaded with 
DxOG514 were isolated from HEK293T cells. Vehicle DMSO control, EN6 (25 μM), or 
BafA1 (200 nM) were added along with 5 mM ATP and MgCl2 were added at the start of 
the experiment and quenching of fluorescence emission over time was measured (see 
methods section for details). Data shown are from n=4 biologically independent samples/
group. (f) Effect of EN6 and bafilomycin treatment on TDP-43 aggregate clearance. U2OS 
cells expressing an IPTG-inducible GFP-TDP-43 were co-treated with vehicle DMSO, IPTG 
(50 μM), IPTG and EN6 (25 μM), or IPTG, EN6, and bafilomycin (0.2 μM) for 7 h. Cells 
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were stained with Hoechst 33342 (blue) and GFP-TDP-43 puncta (green) were imaged by 
confocal fluorescence microscopy in (f). Microscopy images are representative images from 
n=26 individual cells from 3 biologically independent samples/group. Scale bar in (f) 
denotes 10 μm. Data shown in (b, d, and e) as average ± sem. Statistical significance was 
calculated with unpaired two-tailed Student’s t-tests for (b, d) and with a paired t-test of all 
data for each group in (e). Significance is expressed as *p=8.0×10−7, 4.0×10−5, 4.4×10−4, 
3.0×10−3, 1.9×10−6, 1.5×10−4, 4.6×10−4, 4.7×10−5, 1.7×10−6, 1.4×10−6 for CTSA, CTSB, 
CTSF, HEXB, CLN3, CLCN7, ATP6V0D1, ATP6V0E1, LAMP1, P62, respectively, 
compared to 0 h control groups for (b); *p=1.5×10−5, 6.4×10−4, 4.5×10−3 for BafA1, EN6, 
and BafA1/EN6 groups, respectively, compared to vehicle-treated control groups and 
#p=3.1×10−4 compared to EN6-treated groups for (d); *p<0.0001 compared to vehicle-
treated control groups in (e).
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Figure 5. EN6 inhibits mTORC1 signaling in mice.
(a, b) mTORC1 signaling in mouse heart (a) and skeletal muscle (b). C57BL/6 male mice 
were treated intraperitoneally with vehicle (18:1:1 saline:ethanol:PEG40), rapamycin (10 
mg/kg) or EN6 (50 mg/kg) for 4 h. mTORC1 and AKT signaling and autophagy markers 
LC3B and p62 levels were measured by Western blotting and quantified by densitometry. 
LC3BII and p62 levels were normalized to actin loading controls. pS6, p4EBP1, pULK1, 
and pAKT were normalized to total S6, 4EBP1, ULK1, and AKT protein levels. Original gel 
images for (a) and (b) are in Supplementary Fig. 11a and 11b, respectively. All normalized 
values were then normalized to vehicle-treated control levels. Data shown are average ± 
sem, n=4 biologically independent animals/group. Statistical significance was calculated 
with unpaired two-tailed Student’s t-tests. Significance is expressed compared to vehicle-
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treated control groups as *p=7.3×10−8, 6.6×10−8 in (a) and *p=1.0×10−9, 1.0×10−9 in (b) 
for rapamycin and EN6 treatment groups, respectively, for p-S6 levels; *p=7.5×10−5 in (a), 
2.5×10−7 in (b) for EN6 treatment groups for p-4EBP1 levels; *p=5.9×10−7 for EN6-treated 
groups in (a) and *p=3.6×10−4, 4.1×10−4 for rapamycin and EN6-treated groups, 
respectively, in (b) for p-ULK1; *p=9.3×10−3, 6.8×10−6 in (a) and *p=1.1×10−4, 2.2×10−3 
in (b) for rapamycin and EN6-treated groups, respectively, for LC3BII levels; *p= 6.4×10−4, 
2.2×10−3 for (a) and (b), respectively, for EN6-treated groups for p62 levels.
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Figure 6. 
Scheme of v-ATPase-mTORC1 regulation of autophagy and mechanism of EN6 action. 
(top) Under full nutrient conditions, the Ragulator-Rag GTPases recruit mTORC1 to the 
lysosomal surface, where mTORC1 kinase function is activated, leading to pro-growth 
signaling and suppression of autophagy via inhibitory phosphorylation of ULK1 and TFEB. 
The nutrient-induced switch of the Rag GTPases from the inactive to the active, mTORC1-
binding state requires several upstream factors including the v-ATPase. (bottom) By 
covalently modifying Cys277 in the ATP-hydrolyzing domain of the v-ATPase, EN6 causes 
its physical and functional decoupling from the Ragulator-Rag GTPase complex. This leads 
to mTORC1 release to the cytoplasm and its inactivation, triggering autophagy initiation and 
transcriptional upregulation of autophagic-lysosomal biogenesis via TFEB. Additionally, 
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EN6-mediated modification boosts the rate of proton pumping by the v-ATPase, leading to 
increased acidification of the lysosomal lumen. Combined mTORC1 inhibition and v-
ATPase stimulation by EN6 lead to increased cellular clearance.
Yik-Sham Chung et al. Page 32
Nat Chem Biol. Author manuscript; available in PMC 2020 January 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
